Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01504906 · ClinicalTrials.gov registry record · Phase 1

Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor

A Phase 1 study of Healthy, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT01504906 is a Phase 1 study of Healthy that has completed, run by AstraZeneca. The registered enrollment target is 20 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01504906, a Phase 1 study of Healthy, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the effect of Cyclosporine on the blood levels of Ticagrelor.

Conditions Studied

Interventions

  • DRUG cyclosporine
  • DRUG ticagrelor

Study Locations (1)

Kansas

  • Research site - Overland Park

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2012-01
Est. Completion 2012-06
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT01504906

The ClinicalTrials.gov registry entry for NCT01504906 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which cyclosporine is the first listed.

NCT01504906 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT01504906 about?

NCT01504906 is a clinical study titled "Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor". The purpose of this study is to assess the effect of Cyclosporine on the blood levels of Ticagrelor.

What is the current status of trial NCT01504906?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-01. Estimated completion is 2012-06.

What conditions does trial NCT01504906 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01504906?

The interventions under investigation include: cyclosporine (DRUG), ticagrelor (DRUG).

Who is sponsoring clinical trial NCT01504906?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01504906 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.